Last reviewed · How we verify
LORAJMINE
LORAJMINE is a lorajmine drug. It is currently in Phase 2 development.
Lorajmine is thought to work by interacting with a specific biological target, but the exact mechanism is not well understood.
LORAJMINE, also known as Ajmaline 17-(Chloroacetate) Monohydrochloride, is being studied in clinical trials for various heart conditions, including Brugada Syndrome, Atrial Fibrillation, Tachycardia, Ventricular Fibrillation, and Channelopathies. The exact mechanism of LORAJMINE is not specified in the provided information, but it is being compared to other interventions such as flecainide and ajmaline in these trials.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | LORAJMINE |
|---|---|
| Drug class | lorajmine |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have locks on them, and lorajmine is a key that fits into one of those locks. When it binds to the lock, it can affect how the cell works, but the details of how it does this are not yet clear.
Approved indications
Common side effects
Key clinical trials
- Artificial Intelligence for the Prioritization of Genetic Background in Brugada Syndrome
- Feasibility of Improving Risk Stratification in Brugada Syndrome
- Defining the Electrocardiographic Effect of Propofol on the Ajmaline Provocation Drug Challenge: A Prospective Trial
- Right Ventricle Morphology and Hemodynamics in BrS
- The Response To Ajmaline Provocation in Healthy Subjects (PHASE2)
- AnalyST & Brugada Syndrome - Feasibility Study (NA)
- Echocardiography During Ajmaline Test
- Epicardial Ablation in Brugada Syndrome (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LORAJMINE CI brief — competitive landscape report
- LORAJMINE updates RSS · CI watch RSS
Frequently asked questions about LORAJMINE
What is LORAJMINE?
How does LORAJMINE work?
What drug class is LORAJMINE in?
What development phase is LORAJMINE in?
Related
- Drug class: All lorajmine drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing